Adjuvant therapy for high-risk primary and resected metastatic melanoma (Q35048323)

6 August 2017

1 reference

title

Adjuvant therapy for high-risk primary and resected metastatic melanoma (English)

1 reference

6 August 2017

1 reference

P Hersey

1

1 reference

6 August 2017

1 January 2003

1 reference

Internal Medicine Journal

6 August 2017

1 reference

6 August 2017

33

1 reference

6 August 2017

1-2

1 reference

6 August 2017

33-43

1 reference

The role of adjuvant therapy in melanoma management

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Advances in the non-surgical treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Outcome of patients with melanoma and histologically negative sentinel lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Molecular staging of malignant melanoma: correlation with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

TRAIL: a molecule with multiple receptors and control mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00289.X

10.1046/J.1445-5994.2002.00289.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12534876